<DOC>
	<DOCNO>NCT02073994</DOCNO>
	<brief_summary>The purpose Phase I , multicenter study evaluate safety , pharmacokinetics , pharmacodynamics clinical activity AG-120 advance solid tumor , include glioma , harbor IDH1 mutation . The first portion study dose escalation phase cohorts patient receive ascend oral dos AG-120 determine maximum tolerate dose ( MTD ) and/or recommend Phase II dose . The second portion study dose expansion phase four arm patient receive AG-120 evaluate safety , tolerability , clinical activity recommend Phase II dose . Anticipated time study treatment disease progression , unacceptable toxicity occur Investigator discretion .</brief_summary>
	<brief_title>Study Orally Administered AG-120 Subjects With Advanced Solid Tumors , Including Glioma , With IDH1 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<criteria>Key 1 . Dose Escalation 1 . Subjects must histologically cytologically confirm , IDH1 genemutated advanced solid tumor , include glioma , recur progress follow standard therapy , respond standard therapy . 2 . Subjects must evaluable disease RECIST v1.1 subject without glioma RANO criterion subject glioma . 2 . Dose Expansion : Cholangiocarcinoma 1 . Subjects must histologicallyconfirmed diagnosis IDH1 genemutated cholangiocarcinoma Stage II , III , IV ( intrahepatic , extrahepatic perihilar ) eligible curative resection , transplantation , ablative therapy . Tumors mixed histology allow . 2 . Cholangiocarcinoma subject must progress follow gemcitabinebased regimen . 3 . Cholangiocarcinoma subject must radiographically measurable disease least one site previously treat radiation , chemoembolization , radioembolization , local ablative procedure ; new area tumor progression within adjacent previouslytreated lesion , clearly measurable radiologist , acceptable . 3 . Dose Expansion : Chondrosarcoma . Subjects must IDH1 genemutated chondrosarcoma either locally advanced metastatic amenable complete surgical excision . 4 . Dose Expansion : Nonenhancing Glioma 1 . Subjects must progressive glioma solely nonenhancing MRI . 2 . Progression glioma must occur 12 month less . 3 . Subject must available least 3 prior full set scan ( include screen ) , separate least 2 month less equal 5 mm slice thickness 1 mm interslice gap either 2D T2 weight image , 3D T2 weight image , FLAIR . 4 . Subjects must prior surgery ( biopsy allow ) radiation therapy within 6 month enrollment . 5 . Dose Expansion : Solid Tumors Not Otherwise Eligible Cholangiocarcinoma , Chondrosarcoma , Nonenhancing Glioma Cohorts 1 . IDH1 genemutated solid tumor refractory conventional therapy subject tolerate conventional therapy 2 . Subjects must radiographically measurable disease least one site previously treat radiation , chemoembolization , radioembolization , local ablative procedure ; new area tumor progression within adjacent previouslytreated lesion , clearly measurable radiologist , acceptable . 6 . Subject must ≥18 year age . 7 . Subjects must document IDH1 genemutated disease base local test evaluation . ( Centralized testing perform retrospectively . ) 8 . Subjects must amenable serial peripheral blood sampling , urine sampling , biopsy study . 9 . Subject must able understand willing sign inform consent . A legally authorize representative may consent behalf subject otherwise unable provide inform consent , acceptable approve site and/or site 's Institutional Review Board ( IRB ) . 10 . Subjects must ECOG PS 0 1 . 11 . Subjects must expect survival ≥3 month . 12 . Subjects must adequate bone marrow function evidence : 1 . Absolute neutrophil count ≥1.5 ×109/L ; 2 . Hemoglobin &gt; 9 g/dL ( Subjects allow transfused level ) 3 . Platelets ≥ 75 × 109/L . 13 . Subjects must adequate hepatic function evidence : 1 . Serum total bilirubin ≤1.5 × upper limit normal ( ULN ) , unless consider due Gilbert 's disease disease involvement follow approval Medical Monitor ; 2 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) ≤2.5 × ULN . For subject bone metastases and/or suspect diseaserelated liver biliary involvement , ALP must ≤5 × ULN . 14 . Subjects must adequate renal function evidence : a. Serum creatinine ≤2.0 × ULN OR b. Creatinine clearance &gt; 40 mL/min base CockroftGault glomerular filtration rate ( GFR ) estimation : ( 140 Age ) x ( weight kg ) x ( 0.85 female ) /72 x serum creatinine 15 . Subjects must recover clinically relevant toxic effect prior surgery , radiotherapy , therapy intend treatment cancer . ( For example , subject residual Grade 1 toxicity stable Grade 2 peripheral neuropathy due prior chemotherapy allow approval Medical Monitor . ) 16 . Female subject reproductive potential must agree undergo medically supervised pregnancy test prior start study drug . The first pregnancy test perform screening ( within 7 day prior first study drug administration ) , day first study drug administration confirm negative prior dosing . Subjects reproductive potential define sexually mature woman undergone hysterectomy , bilateral oophorectomy tubal occlusion naturally postmenopausal ( i.e. , menstruate ) least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . Females reproductive potential , well fertile men partner female reproductive potential , must agree abstain sexual intercourse use two highly effective form contraception time give informed consent , study 90 day ( female male ) follow last dose AG120 . A highly effective form contraception define hormonal oral contraceptive , injectables , patch , intrauterine device , doublebarrier method ( e.g. , synthetic condom , diaphragm , cervical cap spermicidal foam , cream , gel ) , male partner sterilization . 1 . Subjects receive systemic anticancer therapy radiotherapy &lt; 21 day prior first day study drug administration . 2 . Subjects receive investigational agent &lt; 14 day prior first day study drug administration . In addition , first dose AG120 occur period ≥5 halflives investigational agent elapse . 3 . Subjects take follow sensitive cytochrome P450 ( CYP ) 3A4 substrate medication exclude study unless transfer medication prior enrolling : alfentanil , aprepitant , budesonide , buspirone , conivaptan , darifenacin , darunavir , dronedarone , eletriptan , eplerenone , felodipine , indinavir , fluticasone , lopinavir , lovastatin , lurasidone , maraviroc , midazolam , nisoldipine , quetiapine , saquinavir , sildenafil , simvastatin , tolvaptan , tipranavir , triazolam , ticagrelor , vardenafil and/or CYP2B6 substrate : bupropion , efavirenz . 4 . Subjects take follow Pglycoprotein ( Pgp ) transportersensitive substrate medication exclude study unless transfer medication prior enrolling : aliskiren , ambrisentan , colchicine , dabigatran etexilate , digoxin , fexofenadine , maraviroc , posaconazole , ranolazine , saxagliptin , sitagliptin , talinolol , tolvaptan . 5 . Subjects potentially curative anticancer therapy available . 6 . Subjects pregnant breast feeding . 7 . Subjects active severe infection require antiinfective therapy unexplained fever &gt; 38.5°C screen visit first day study drug administration ( discretion Investigator , subject tumor fever may enrol ) . 8 . Subjects know hypersensitivity component AG120 . 9 . Subjects New York Heart Association ( NYHA ) Class III IV congestive heart failure leave ventricular ejection fraction ( LVEF ) &lt; 40 % echocardiogram ( ECHO ) multigated acquisition ( MUGA ) scan within approximately 28 day C1D1 . 10 . Subjects history myocardial infarction within last 6 month . 11 . Subjects know unstable uncontrolled angina pectoris . 12 . Subjects know history severe and/or uncontrolled ventricular arrhythmia . 13 . Subjects heartrate correct QT ( QTc ) interval ≥ 450 msec factor increase risk QT prolongation arrhythmic event ( e.g. , heart failure , hypokalemia , family history long QT interval syndrome ) . Subjects right bundle branch block prolong QTc interval review Medical Monitor potential inclusion . 14 . Subjects take medication know prolong QT interval ( see Section 9.11.3 ) . 15 . Subjects know infection human immunodeficiency virus ( HIV ) active hepatitis B C. 16 . Subjects medical psychological condition , deem Investigator likely interfere subject 's ability sign inform consent , cooperate , participate study . 17 . Subjects know dysphagia , shortgut syndrome , gastroparesis , condition limit ingestion gastrointestinal absorption drug administer orally . 18 . Subjects brain metastasis untreated , symptomatic , require therapy control symptom ; radiation , surgery , therapy , include use control symptom , within 2 month first dose . Subjects glioma stable , steroid dose regimen 5 day prior screen MRI may permit enroll Medical Monitor approval . 19 . Subjects history Grade 4 astrocytoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chondrosarcoma</keyword>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>glioma</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>IDH1</keyword>
	<keyword>AG-120</keyword>
</DOC>